Loading...
Loading...
Vertex Pharmaceuticals Incorporated
VRTX dipped 5.91% to $50 in the pre-market session. VRTX reported interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.
Brigham Exploration Company
BEXP dropped 1.06% to $27 in the pre-market trading. BEXP's trailing-twelve-month ROA is 3.59%.
Aixtron SE
AIXG fell 1.06% to $38.42 in the pre-market session. AIXG's PEG ratio is 7.88.
Teva Pharmaceutical Industries Limited
TEVA moved down 0.20% to $49.46 in the pre-market session. TEVA's trailing-twelve-month ROA is 7.57%.
Read more
from Benzinga's Markets.© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPre-Market OutlookMarketsMoversBiotechnologyEnergyHealth CareInformation TechnologyOil & Gas Exploration & ProductionPharmaceuticalsSemiconductor EquipmentTop Pre-Market NASDAQ Losers
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in